Fachkrankenhaus Coswig GmbH

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis5 trials
• Lung cancer1 trial

Phase

• Phase 23 trials
• Phase 33 trials

Status

• Completed4 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim1 trial
• Bristol-Myers Squibb1 trial
• CSL Behring1 trial
• H e x a l AG1 trial
• Novartis Pharma AG1 trial
• and 1 more

Running trials

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis1 recruiting

Closed trials

• Completed

  A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

  2023-506882-70-00· Phase 3· H e x a l AG· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)

  2023-508729-28-00· Phase 2· Novartis Pharma AG· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source